The study was carried out at 24 clinical sites across the UK and included 303 participants.

Abbott (NYSE:ABT) today announced results from a trial demonstrating better glucose outcomes for users of continuous glucose monitors (CGMs).

About 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors manufactured by Abbott were recalled in November, because they might give wrong readings.

Abbott (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) ...

Abbott announced results from its REFLECT real-world studies that show the use of FreeStyle Libre continuous glucose monitoring (CGM) technology is associated with a significant reduction in the risk ...

When the FDA approved Abbott’s FreeStyle Libre Flash continuous glucose monitoring (CGM) system in September 2017, diabetes advocates hailed the move as long overdue and one that might lead to greater ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA granted clearance for a standalone reader to be ...

Abbott announced yesterday that its recently cleared FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system is now covered by the Centers for Medicare and Medicaid Services (CMS), and ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

The factory-calibrated continuous glucose monitoring (CGM) system is being touted as less expensive, and a spokeswoman said it will not require bundling with a meter, which is required for a ...

Abbott Laboratories ABT recently received the CE Mark for its next-generation FreeStyle Libre 3 system. The regulatory approval makes the sensory device eligible for use for the diabetics living in ...

FreeDM2 randomized controlled trial shows Libre technology helps people with type 2 diabetes on basal insulin improve glucose management: Abbott Park, Illinois Saturday, March 14, ...